Therapeutics
Therapeutics
We are applying our platform, data and therapeutics expertise to identify, validate and develop novel therapeutic candidates that act on the immune system to reverse disease and dysfunction.
Ways we partner
We collaborate with leading biopharmaceutical companies and academic research institutions to identify and improve novel therapeutics and unlock biological insights using our platform.
Drug discovery & development
Immunai leverages our platform to support partners at various stages of drug development, including target discovery, target validation, compound validation and clinical trial optimization.
Data sharing
For select projects, Immunai retains data rights and company improvements, including algorithms and infrastructure resulting through collaborations. These are fed back into AMICA™ to generate downstream transfer learning insights.
30+ partnerships
Immunai has signed 30+ partnerships with leading biopharma companies and academic institutions, including the Baylor College of Medicine.
Areas we partner
We have built proprietary knowledge libraries and deep expertise in a variety of immune cell compartments, including T cell and myeloid suppression.
Immunai’s computational and experimental infrastructure is focused on understanding core pathways and mechanisms within each compartment, and the intersection of these compartments to comprehensively study disease etiology, and how to reverse it.
Our long term vision is pan-immune, but we are starting with therapeutics programmes in immune-oncology and autoimmune diseases.
How we partner
The drug discovery & development process is complex, time-consuming and costly. Immunai’s platform has applicability at key stages of this process, including:
-
Initiate mAb campaigns
Generate tool reagents and initiate efforts to produce fully humanized, optimal lead drug candidates
In vitro / functional genomics
Knock out genes in pooled experiments with disease relevant models and assess activity of drug candidates
In silico
Leverage computational models or simulations to generate predictions for a wide variety of possible perturbations, then select those closest to our target model system.
In vivo
Final validation, assess PK/PD and activity in appropriate organoid and mouse models
Partnerships
We have dozens of strategic partnerships with academic research institutions and biopharmaceutical companies, working to discover and advance novel therapeutics and accelerate R&D.
We are interested in strategic (asset and platform-based) partnerships with industry and academic leaders who share our vision of mapping the immune system to accelerate the development of therapeutics.